Pulmonary mRNA-LNP vaccines for rapid and durable protection against bacterial infection
Academic source · Nature Communications
Source published:
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What the paper reports
Researchers designed a pulmonary mRNA-LNP vaccine that combines early innate immune activation with later antigen-specific protection. Intratracheal vaccination primed neutrophils and macrophages and subsequently generated adaptive responses against Pseudomonas aeruginosa, including drug-resistant isolates. Single-cell profiling supported a coordinated immune mechanism. The protection experiments were conducted in female mice, rather than patients.
Why this paper is included
Connects local delivery with the post-vaccination immunity gap; mouse protection does not establish safety or effectiveness in human respiratory infections.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections